Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Industry group warns S.1497 could limit access to compounded 503B medications used by hospitals
Summary
An industry advocate told the Joint Committee the state should not restrict pharmacies’ ability to dispense compounded medications produced by FDA‑registered outsourcing facilities (503B), saying such a change could harm patients who rely on specialized formulations.
A representative of outsourcing‑facility stakeholders urged the Joint Committee on Public Health to oppose S.1497, which the witness said would restrict pharmacies’ ability to dispense compounded drug products from FDA‑registered outsourcing facilities (503B facilities).
Lee Rosebush said the Massachusetts Board of Pharmacy…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
